Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DIABETIC KIDNEY DISEASE

Potential cardiorenal benefits of efpeglenatide in diabetes

Building on previous cardiovascular outcome trials with glucagon-like peptide 1 receptor agonists, the AMPLITUDE-O trial reported significant improvements in major adverse cardiovascular and kidney outcomes with efpeglenatide in type 2 diabetes. A longer-term trial with dose-dependent analysis on kidney outcome components will better define the effects of efpeglenatide in the diabetic kidney.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sposito, A. C., Berwanger, O., de Carvalho, L. S. F. & Saraiva, J. F. K. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovas. Diabetol. 17, 157 (2018).

    Article  CAS  Google Scholar 

  2. Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108269 (2021).

    Article  PubMed  Google Scholar 

  3. Zelniker, T. A. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139, 2022–2031 (2019).

    Article  CAS  Google Scholar 

  4. Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018).

    Article  CAS  Google Scholar 

  5. Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

    Article  CAS  Google Scholar 

  6. Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).

    Article  CAS  Google Scholar 

  7. Bentley-Lewis, R. et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am. Heart J. 169, 631–638 (2015).

    Article  CAS  Google Scholar 

  8. Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).

    Article  CAS  Google Scholar 

  9. van der Aart-van der Beek, A. B. et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes. Metab. 22, 2493–2498 (2020).

    Article  Google Scholar 

  10. Bethel, M. A. et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes https://doi.org/10.2337/db18-522-P (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mark E. Cooper.

Ethics declarations

Competing interests

M.E.C. has previously reviewed grants and has been a member of honorary advisory boards for companies that manufacture GLP1 agonists and other glucose-lowering drugs, including AstraZeneca, Novo Nordisk, Boehringer Ingelheim, MSD, Novartis, Sanofi and Eli Lilly and Company. J.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, J., Cooper, M.E. Potential cardiorenal benefits of efpeglenatide in diabetes. Nat Rev Nephrol 17, 708–709 (2021). https://doi.org/10.1038/s41581-021-00475-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-021-00475-7

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing